A prospective trial comparing 3 antipsychotic drugs revealed that clozapine is most likely to produce metabolic changes that point the way to metabolic syndrome.
However, clozapine was also most likely to control violent behaviour and metabolic consequences were most apparent for African American, researchers stated here at the 162nd Annual Meeting of the American Psychiatric Association (APA).
Menahem Krakowski, MD, New York University, New York, and Nathan Kline Institute, Orangeburg, New York, presented the findings of a randomised, double-blind study on May 20.
The study included 110 inpatients with schizophrenia or schizoaffective disorder who were randomised to receive clozapine (n = 34), olanzapine (n = 31), or haloperidol (n = 28).
At study entry, 93 patients gave blood samples for measuring fasting glucose, cholesterol and triglycerides and had at least 1 more sample collected during the 12 weeks of the study. The patients had a history of physical assaults.
READ MORE @ DOCTOR'S GUIDE
Showing posts with label haloperidol. Show all posts
Showing posts with label haloperidol. Show all posts
Thursday, May 21, 2009
Wednesday, January 28, 2009
Most Second-Generation Antipsychotics Effective for Treatment of Negative Schizophrenia Symptoms: Presented at EPA
Amisulpride and ziprasidone show better overall effects in comparison with other second-generation antipsychotics in the of negative symptoms of schizophrenia, according to results of 2 meta-analyses of randomised controlled trials.
Principal investigator Javier Rejas, MD, PhD, Medical Unit, Health Outcomes Research, Pfizer España, Madrid, Spain, presented these results on January 27 here at the 17th European Congress of Psychiatry, organised by the European Psychiatric Association (EPA).
While research has demonstrated the efficacy of numerous first-generation antipsychotics, such as haloperidol, for treatment of positive symptoms of schizophrenia, negative symptoms are difficult to treat and can result in severe impairment and poor quality of life, said Dr. Rejas.
His research team therefore conducted 2 meta-analyses to compare the efficacy of second-generation antipsychotics versus haloperidol and versus placebo in the treatment of negative schizophrenia symptoms.
READ MORE @ DOCTOR'S GUIDE
Principal investigator Javier Rejas, MD, PhD, Medical Unit, Health Outcomes Research, Pfizer España, Madrid, Spain, presented these results on January 27 here at the 17th European Congress of Psychiatry, organised by the European Psychiatric Association (EPA).
While research has demonstrated the efficacy of numerous first-generation antipsychotics, such as haloperidol, for treatment of positive symptoms of schizophrenia, negative symptoms are difficult to treat and can result in severe impairment and poor quality of life, said Dr. Rejas.
His research team therefore conducted 2 meta-analyses to compare the efficacy of second-generation antipsychotics versus haloperidol and versus placebo in the treatment of negative schizophrenia symptoms.
READ MORE @ DOCTOR'S GUIDE
Monday, March 31, 2008
Second-Generation Antipsychotics Are No Better Than First-Generation Drugs for Schizophrenia
Second-generation antipsychotic drugs are not necessarily better than the first-generation drug haloperidol at treating a first episode of schizophrenia. This is the conclusion of authors of an article published in this week's issue of The Lancet.
Second-generation drugs, introduced over a decade ago, are purported to be more effective and less likely to induce motor side effects, such as stiffness and tremors, than first-generation drugs. However, results from studies comparing the 2 types of drugs have not been reliable -- studies have over-represented men and under-represented those with other issues such as drug abuse. Moreover, these trials were often too short. The question of which drugs are more effective is an important one, as many of the newer drugs are more expensive.
READ MORE @ DOCTOR'S GUIDE
Second-generation drugs, introduced over a decade ago, are purported to be more effective and less likely to induce motor side effects, such as stiffness and tremors, than first-generation drugs. However, results from studies comparing the 2 types of drugs have not been reliable -- studies have over-represented men and under-represented those with other issues such as drug abuse. Moreover, these trials were often too short. The question of which drugs are more effective is an important one, as many of the newer drugs are more expensive.
READ MORE @ DOCTOR'S GUIDE
Subscribe to:
Posts (Atom)
